Enfuvirtide
Enfuvirtide (INN), sold under the brand name Fuzeon, is an HIV fusion inhibitor, the first of a class of antiretroviral drugs used in combination therapy for the treatment of AIDS/HIV.
Clinical data | |
---|---|
Trade names | Fuzeon |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603023 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 84.3% (SC) |
Protein binding | 92% |
Metabolism | Liver |
Elimination half-life | 3.8 hours |
Excretion | unknown |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.169.201 |
Chemical and physical data | |
Formula | C204H301N51O64 |
Molar mass | 4491.945 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.